Dexamethasone Phosphoric Acid

Summary

Dexamethasone Phosphoric Acid (CHEMBL1201302) is an approved small-molecule glucocorticoid receptor agonist; indicated across 5 conditions including anterior uveitis and dry eye syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 15
• Chemistry: 472.4 Da · C22H30FO8P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201302
Name	Dexamethasone Phosphoric Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9400
ChEBI	CHEBI:68637
Molecular formula	C22H30FO8P
Molecular weight	472.4
InChIKey	VQODGRNSFPNSQE-CXSFZGCWSA-N

SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)(O)O)O)C)O)F)C

IUPAC name: [2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] dihydrogen phosphate

ChEBI definition: A steroid phosphate that is the 21-O-phospho derivative of dexamethasone.

Pharmacological roles (ChEBI): glucocorticoid receptor agonist.

Also known as: Dexamethasone phosphoric acid, Dexamethasone phosphate, DEXAMETHASONE PHOSPHORIC ACID, dexamethasone phosphate

Parent form; salt/anhydrous children: CHEMBL1200637, CHEMBL2021430

Patent coverage: 587 distinct patent families (2,331 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
anterior uveitis	3	MONDO:0006651	EFO:1000811
dry eye syndrome	3	MONDO:0006733	EFO:1000906
cataract	3	MONDO:0005129	MONDO:0005129
scleritis	1	MONDO:0001718	MONDO:0001718

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE4	7
PHASE3	3
Not specified	3
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05793060	PHASE4	RECRUITING	Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Intermediate Cervical Plexus Block
NCT01372904	PHASE4	COMPLETED	Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment
NCT03664037	PHASE4	COMPLETED	Dexamethasone Blunts the Hypotensive Effect of Spinal Anesthesia in Geriatric Patients Undergoing Lower Limb Orthopedic Surgeries
NCT03675555	PHASE4	COMPLETED	Prophylactic Mirtazapine or Dexamethasone for Post-spinal Anesthesia Shivering
NCT03876041	PHASE4	COMPLETED	Evaluation of Corticosteroid in Systemic Inflammatory Response Syndrome
NCT04778267	PHASE4	COMPLETED	Effectiveness of Combined Erector Spinae and Pecto-intercostal Fascial Plane Blocks Versus Thoracic Paravertebral Block in Perioperative Pain in Modified Radical Mastectomy
NCT04816097	PHASE4	UNKNOWN	Dexamethasone Before Elective Cesarean Section at Term in Reducing Neonatal Respiratory Distress Syndrome
NCT07305987	PHASE3	RECRUITING	PRO-232 in Patients Subjected to Cataract Surgery
NCT02749162	PHASE3	COMPLETED	Perineural Dexamethasone in Femural Nerve Block After Ligament Reconstruction
NCT05000658	PHASE3	COMPLETED	Efficacy of Soluble Dexamethasone in Refractory Sciatica
NCT02415335	PHASE2	COMPLETED	Dexamethasone Preoperative for Patients Undergoing Laparoscopy for Suspected Appendicitis
NCT03180255	PHASE2	COMPLETED	Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery
NCT05635227	Not specified	RECRUITING	Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac Surgery
NCT02026479	Not specified	UNKNOWN	Sudden Hearing Loss Multi-center Clinical Trial
NCT04762381	Not specified	COMPLETED	Dexamethasone and Robotic-assisted Hysterectomy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).